TRIM52 Protects Against Doxorubicin‐Induced Cardiac Inflammation, Oxidative Stress and Cardiac Injury
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Zhaoxia Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Ningbo University, The Key Laboratory of Precision Medicine for Atherosclerotic Diseases o…. Hauptthemen laut MEDLINE: Oxidative Stress, Doxorubicin, Inflammation, Tripartite Motif Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Project of Science and Technology on Traditional Chinese Medicine in Zhejiang Province, Key Public Welfare Project of Ningbo.
Abstract (Originalsprache)
Tripartite motif 52 (TRIM52) has been identified as a key regulator of inflammatory responses. However, its involvement in doxorubicin (DOX)‐induced cardiotoxicity (DIC) and the underlying molecular mechanisms remain poorly understood. To investigate the functional role of TRIM52, we employed an adeno‐associated virus serotype 9 (AAV9) delivery system to achieve cardiac‐specific Trim52 knockout via tail‐vein injection. C57BL/6 mice received intraperitoneal DOX (5 mg/kg, administered once a week, with a total cumulative dose of 15 mg/kg). Myocardial injury was evaluated by histopathological assessment and molecular profiling of cardiac tissues, complemented by in vitro mechanistic studies using neonatal mouse cardiomyocytes. In vivo and in vitro studies revealed that DOX treatment significantly upregulated TRIM52 expression. Trim52 deficiency effectively mitigated DOX‐induced cardiac injury and dysfunction, concomitantly attenuating oxidative stress and inflammatory responses. Mechanistically, Trim52 deletion markedly enhanced PI3K and AKT phosphorylation, indicating that PI3K/AKT pathway activation underlies the cardioprotective effects of TRIM52 deficiency. Our findings demonstrate that TRIM52 deletion activates PI3K/AKT signalling and attenuates DOX‐induced oxidative and inflammatory myocardial damage. These data identify TRIM52 as a potential therapeutic target for mitigating DIC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Ningbo University, The Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province, Ningbo, China.
- Health Science Center, Ningbo University, Ningbo, China.
ORCID-Profile: Weiping Du
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- Project of Science and Technology on Traditional Chinese Medicine in Zhejiang Province
- Key Public Welfare Project of Ningbo
- Key Technology R&D Program of Ningbo
- Zhejiang Vanguard and Leading Goose R&D Program
- Zhejiang Provincial Health and Wellness Industry Science and Technology Plan
Zitieren
APA
Zhang, Z., Chen, H., Hu, Y., Zhou, J., Lu, Y., Du, T., Jia, Z., Su, J., & Du, W. (2026). TRIM52 Protects Against Doxorubicin‐Induced Cardiac Inflammation, Oxidative Stress and Cardiac Injury. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71016
Vancouver
Zhang Z, Chen H, Hu Y, Zhou J, Lu Y, Du T, et al. TRIM52 Protects Against Doxorubicin‐Induced Cardiac Inflammation, Oxidative Stress and Cardiac Injury. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71016
BibTeX
@article{Zhang2026,
author = {Zhang, Zhaoxia and Chen, Hongzhen and Hu, Yingchu and Zhou, Jiedong and Lu, Yiqi and Du, Tingsha and Jia, Zhenyu and Su, Jia and Du, Weiping},
title = {TRIM52 Protects Against Doxorubicin‐Induced Cardiac Inflammation, Oxidative Stress and Cardiac Injury},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71016}
}
EUVIMED